Exenatide

Research Papers and Clinical Trials

Recent research on exenatide and GLP-1 receptor agonists spans multiple therapeutic areas, though specific studies focusing exclusively on exenatide are limited in the available evidence.

Clinical Trial Evidence

Several completed clinical trials have evaluated exenatide's effectiveness in diabetes management. The DURATION-1 trial (NCT00308139) was a Phase 3 study examining the long-acting release formulation's effects on glucose control and safety in patients with type 2 diabetes. Another Phase 3 trial (NCT00518882) compared exenatide to liraglutide as add-on treatments for blood glucose control in type 2 diabetes patients. A Phase 4 study (NCT00974272) investigated exenatide's effects on postprandial hyperlipidemia and inflammation, expanding beyond glucose control to examine cardiovascular-related outcomes.

Current research includes an early-phase trial (NCT07347080) testing a novel exenatide circular RNA-lipid nanoparticle formulation in Chinese patients with type 2 diabetes, representing advances in drug delivery technology. Additionally, one completed study (NCT04909333) explored exenatide's diagnostic potential for identifying endogenous hyperinsulinemic hypoglycemia.

Recent Research Directions

While specific exenatide studies are not detailed in the recent literature provided, broader GLP-1 receptor agonist research from 2026 includes systematic reviews and meta-analyses examining weight management effects in both diabetic and non-diabetic populations, as well as applications in psychiatric conditions. Network meta-analyses have compared GLP-1 receptor agonists to oral medications for insulin discontinuation in type 2 diabetes and evaluated their use for weight reduction in patients with schizophrenia taking antipsychotics.

Evidence Limitations

The available evidence provides limited specific details about study designs, sample sizes, or outcomes for the completed exenatide trials. Most recent publications focus on the broader class of GLP-1 receptor agonists rather than exenatide specifically, making it difficult to draw definitive conclusions about exenatide's unique profile compared to other agents in this class.

This synthesis is based on limited available evidence and should not replace consultation with healthcare professionals for treatment decisions.